Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.
Lifecore Biomedical, Inc. (LFCR) reports developments as a fully integrated injectables CDMO focused on sterile pharmaceutical products. The company provides development, fill and finish services for syringes, vials and cartridges, including complex formulations, and manufactures injectable-grade hyaluronic acid for biopharmaceutical and biotechnology customers.
Company news commonly covers financial results, revenue and Adjusted EBITDA guidance, commercial site transfer programs, technical transfer and PPQ work, new CDMO manufacturing service agreements, customer program expansions, cost-containment initiatives, biomanufacturing conference participation and Nasdaq inducement equity grants.
Lifecore Biomedical (NASDAQ: LFCR) will participate in the William Blair 46th Annual Growth Stock Conference in Chicago. The event runs from June 2-4, 2026 at the Loews Chicago Hotel.
CEO Paul Josephs and CFO Ryan Lake will attend and hold investor meetings.
Lifecore Biomedical (NASDAQ: LFCR) reported Q1 2026 results and reaffirmed full-year guidance. Revenues were $23.2M (-34% YoY), gross margin 19.2%, adjusted EBITDA $1.0M, and net loss $15.0M (loss per share $0.43). Liquidity was approximately $38.1M. Company expects 2026 revenue of $120–125M and Adjusted EBITDA of $20.5–25M. Signed three new commercial site transfer programs and completed a January ERP launch to improve controls and costs.
Lifecore Biomedical (NASDAQ: LFCR) will report first-quarter 2026 financial results for the period ended March 31, 2026, on Wednesday, May 6, 2026 before market open. Lifecore management will host a live webcast at 8:00 a.m. Eastern to discuss results. An archived webcast will be available on the company's Investor Events & Presentations page for 30 days.
Lifecore (NASDAQ: LFCR) granted a restricted stock unit award for 5,000 shares as an inducement to a newly hired employee, effective April 20, 2026. The award was approved by the compensation committee under the company’s Equity Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The RSUs vest and will be settled on the third anniversary of the grant date, subject to continued employment, and are governed by an award agreement and the Inducement Plan.
Lifecore Biomedical (NASDAQ: LFCR) will participate at the 12th Annual American Biomanufacturing Summit on April 14-15, 2026 in San Francisco. Lifecore will discuss process development and manufacturing services for injectable programs and staff will be available at Booth 41.
Investors and partners may request meetings via cdmo@lifecore.com.
Lifecore (NASDAQ: LFCR) granted an inducement restricted stock unit award for 18,500 shares to a newly hired employee effective March 25, 2026. The award was approved by the compensation committee under Lifecore’s Equity Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The RSUs vest and settle on the third anniversary of the grant date, subject to continued employment, and are governed by an award agreement and the Inducement Plan.
Lifecore Biomedical (NASDAQ: LFCR) signed two CDMO manufacturing agreements with an existing U.S. biopharmaceutical customer on March 26, 2026. One is a commercial site transfer for a currently marketed product; the other expands manufacture to a second delivery system for an ophthalmic commercial product.
Both programs are additive to Lifecore’s late-stage pipeline, mark the company’s fourth commercial site transfer in five months, and are expected to contribute to 2028 commercial revenue pending completion of PPQ and regulatory requirements.
Lifecore Biomedical (NASDAQ: LFCR) signed a commercial CDMO site transfer agreement to manufacture an established, market-approved aesthetic sterile product for a new customer. Program may generate commercial revenue within 24 months and is cited as contributing to Lifecore's targeted 2029 revenue CAGR of 12%. This is Lifecore's third commercial site transfer since October 2025 and advances its strategy to prioritize lower-risk, late-stage programs and site transfers for faster path to commercial revenue.
Lifecore Biomedical (NASDAQ: LFCR) reported fourth quarter revenues of $35.7M and transition-period revenue of $75.5M for the seven months ended Dec 31, 2025, a 20% increase year-over-year. Gross profit margin improved to 31.4%, operating expenses fell 31%, and Adjusted EBITDA was $13.1M. The company signed five new programs in 2025, launched a new ERP in Jan 2026, ended the quarter with ~$38.9M liquidity, and issued 2026 guidance of $120–$125M revenue and $20.5–$25M Adjusted EBITDA.
Lifecore Biomedical (NASDAQ: LFCR) will participate in the 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum on March 17–18, 2026. Management, including Mr. Josephs, will host a fireside chat at 9:00–9:35am ET on March 17 and will meet with investors.
A live webcast of the fireside chat will be accessible via Lifecore’s Investor Events & Presentations page, with a replay available on the company website after the conference.